---
schema_version: "secwatch.filing_event.v1"
accession: "0001839882-24-003361"
form_type: "8-K"
ticker: null
cik: "0000887247"
company_name: "DMK PHARMACEUTICALS Corp"
filed_at: "2024-02-05T23:59:59+00:00"
generated_at: "2026-06-06T09:37:58.747511+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# DMK Pharmaceuticals files Chapter 11; expects Nasdaq delisting, stock may become worthless

## Summary
- Filed voluntary Chapter 11 petitions on Feb 2, 2024 in Delaware Bankruptcy Court.
- Will operate as debtor-in-possession; seeks court approval to continue paying wages, salaries, benefits.
- Expects Nasdaq delisting notice; will not appeal, so common stock will be delisted.
- Caution: trading in securities highly speculative; stockholders could experience significant or complete loss.

## SEC filing metadata
- accession: 0001839882-24-003361
- form_type: 8-K
- cik: 0000887247
- company_name: DMK PHARMACEUTICALS Corp
- filed_at: 2024-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887247/000183988224003361/0001839882-24-003361-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887247/000183988224003361/dmk-8k_020524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001839882-24-003361
- JSON: https://secwatch.observer/filing/0001839882-24-003361.json
- Plain text: https://secwatch.observer/filing/0001839882-24-003361.txt

## Key facts
- Distress & Bankruptcy
  DMK PHARMACEUTICALS Corp entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2024-02-02).
  - Proceeding: chapter 11
  - Court: United States Bankruptcy Court for the District of Delaware
  - Petition: 2024-02-02
  source text: On February 2, 2024 (the “Petition Date”), DMK Pharmaceuticals Corporation (the “Company”) and certain of its direct and indirect subsidiaries (collectively, the “Company Parties”) commenced bankruptcy cases (the “Chapter 11 Cases”) by filing voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000183988224003361/0001839882-24-003361-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.